Uveal Melanoma
Ireland has possibly highest incidence in the world
Priscilla Lynch
Published: Thursday, September 1, 2016
SYSTEMIC TREATMENTS
Treatments modalities during the course of the study included brachytherapy (63.7 per cent), enucleation of the affected eye (27 per cent) and proton beam radiation (9.2 per cent). Chromosome 3 loss and chromosome 8q gain were identified in 29.3 per cent and 29.7 per cent of cases, respectively. Dr Baily noted that uveal melanoma survival rates are good in Ireland — one-year survival was 95.8 per cent and four-year survival was 84.0 per cent in the study patient population. “Despite the different treatment options available, overall survival in uveal melanoma has not improved. Ultimately we need the development of systemic treatments to improve overall survival rates,” Dr Baily said.CILIARY BODY
Uveal melanoma is the most common primary intraocular malignancy in adults, and involves the iris, ciliary body, or choroid. Despite this, it is still a very rare disease, Dr Baily noted. “With the national diabetic screening service now available (in Ireland), it is likely there will be an increased pick-up of incidental melanomas, due to the large volume of posterior segments being reviewed,” she told EuroTimes. Uveal melanoma is often asymptomatic and therefore picked up during routine eye examinations, Dr Baily noted.Latest Articles
Glaucoma Treatment Under Pressure
New techniques and technologies add to surgeons’ difficult decisions
Outside the Box, Inside the Pipeline
Researchers are tackling glaucoma diagnosis and treatment from all sides.
The EHDS Is Ready for the Green Light
If proposal is approved, Europe could see better access to, and exchange and use of, health data.
From Lab to Life: Corneal Repair Goes Cellular
Long-awaited cellular therapies for corneal endothelial disease enter the clinic.
Balancing Innovation and Safety
Ensuring access to advanced cell therapies amid regulatory overhaul.
With Eyes on Its Future, ESCRS Celebrates Its Past
Winter Meeting offers opportunities to experiment with new concepts and formats.
Best of ESCRS Winter Meeting 2024
Following the New Generation
EDOF IOLs an option for eyes with mild comorbidities, showing potential in mini-monovision strategies.
Refocus on Multifocals
Trifocal IOLs continue to improve as consensus grows regarding indications and contraindications.
Common Myths in Presbyopia Correction
Patient education key to satisfaction with refractive IOLs.